US/Vietnam sign drug safety pact

27 July 2008

The USA and the Socialist Republic of Vietnam have signed a memorandum of understanding to enhance the safety of drugs and medical devices, as well as food and feed, traded between the two nations.

The plan is the product of discussions between US Secretary of Health and Human Services Michael Leavitt and senior Vietnamese officials in Hanoi two months ago and exemplifies the new import safety strategy adopted by the US government in November 2007. Historically, US authorities have primarily relied on intervention at the border to intercept unsafe goods. The new strategy, crafted by a Cabinet-level inter-agency Working Group on Import Safety chaired by Secretary Leavitt, calls for actively working with trading partners to help ensure they build quality into every step of a product's life cycle.

Among others, the MOU calls for cooperation in areas such as: information-sharing by the two governments on their respective regulatory systems, such as details on laws and regulations; guidance documents; lists of drugs approved by the US Food and Drug Administration; and best practices in clinical trials - the HHS/FDA and its counterpart agencies intend to cooperate on training and inspections of clinical trials for the development of medical products.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK







Today's issue

Company Spotlight